3 years ago

Constructive Bio Secures $15 Million Seed Funding for Synthetic Biology Advancements

  • Constructive Bio, a Cambridge, UK-based biotechnology company, raised $15 million in seed funding led by Ahren

  • The funding will be used to build out the technology platforms for commercial application, including assembling synthetic genomes and synthesis of non-natural polymers using bacterial strains

  • The company is based upon two core proprietary platform technologies: large scale DNA assembly and genome reprogramming

  • Together, the MRC technologies will be used by Constructive Bio to synthesize polymers with non-natural amino acids for commercial applications across a range of industries including novel therapeutics and antibiotics, enhanced agriculture, manufacturing and materials.

      • ProblemTechnology

      "Current methods for synthesizing polymers are limited in their ability to create new and innovative materials with desired properties. The current manufacturing processes are also inefficient and expensive. "

      Solution

      "Constructive Bio is developing a new platform technology that enables the synthesis of non-natural polymers using bacterial strains. This technology allows for the creation of polymers with novel properties and improved performance. They are also engineering organisms with resistance to viruses, which can improve yields in bio-manufacturing."

      Covered on